Buy Entero Healthcare Solutions; target of Rs 2100: ICICI Securities

Moneycontrol • 4 days ago

Original source

Key Investment Pillars

  • Entero Healthcare Solutions reported strong Q2FY27 results, with revenue/EBITDA/PAT growing 32.9%/78.3%/44.1% YoY, driven by organic growth and margin expansion.
  • The company's ability to expand its product portfolio and increase wallet share from existing customers has helped it deliver healthy organic growth of 17–20% over the past four quarters.
  • The increasing contribution from MedTech provides an additional growth avenue, given the relatively fragmented nature of the market and the opportunity to consolidate distribution.
  • Entero plans to utilize its operating cash flow of ~INR 2bn in FY27 for pursuing M&A opportunities with relatively larger scale, focusing on portfolio expansion and entry into product categories where it currently has limited presence.

Thesis Validation Checklist

  • Investors should watch for Entero's ability to maintain its organic growth rate, driven by new client additions, higher wallet share from existing clients, and expansion into newer product categories.
  • The company's margin expansion, driven by scale-led procurement, greater share of high-margin MedTech business, and exit from certain low-margin businesses, will be crucial in validating the thesis.
  • Entero's working capital management and its ability to generate operating cash flow will be important signals to monitor, as the company plans to utilize this cash for M&A opportunities and growth initiatives.
  • Regulatory pricing interventions and risks associated with scale-up in past or future acquisitions are potential headwinds to watch out for.